{"id":153,"date":"2019-12-26T17:41:02","date_gmt":"2019-12-26T17:41:02","guid":{"rendered":"http:\/\/www.hepbunited.org\/blog\/?p=153"},"modified":"2019-12-26T17:41:02","modified_gmt":"2019-12-26T17:41:02","slug":"hepatitis-delta-treatment-endpoints-how-do-we-measure-success-in-the-era-of-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.hepbunited.org\/blog\/hepatitis-delta-treatment-endpoints-how-do-we-measure-success-in-the-era-of-emerging-therapies\/","title":{"rendered":"Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?"},"content":{"rendered":"<p>Join us on January 29, 2020 at 11:00 AM EST for a <a href=\"https:\/\/register.gotowebinar.com\/register\/3646690146140403467\" target=\"_blank\" rel=\"noopener\">webinar<\/a> on Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?<\/p>\n<p>Hepatitis delta, a dangerous coinfection of hepatitis B, is estimated to affect between 15 and 70 million people across the world. For decades, the only treatment option has been pegylated interferon; an often difficult drug to tolerate with only a small chance of controlling liver disease. With many new drugs now in clinical trials for hepatitis delta, we must ask, what does successful treatment look like?<\/p>\n<ul>\n<li>How can we measure success?<\/li>\n<li>What does it mean to control hepatitis delta?<\/li>\n<li>Is a cure for hepatitis B the only ideal endpoint of treatment?<\/li>\n<\/ul>\n<p>Join hepatitis delta expert, Dr. Ohad Etzion, as he outlines the challenges in controlling the disease, current clinical trials, and explores ideal endpoints for treatment and control of hepatitis B and delta coinfection.<\/p>\n<p><strong>Register <a href=\"https:\/\/register.gotowebinar.com\/register\/3646690146140403467\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Join us on January 29, 2020 at 11:00 AM EST for a webinar on Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? Hepatitis delta, a dangerous coinfection of hepatitis B, is estimated to affect between 15 and 70 million people across the world. For decades, the only treatment &hellip; <\/p>\n<p><a href=\"https:\/\/www.hepbunited.org\/blog\/hepatitis-delta-treatment-endpoints-how-do-we-measure-success-in-the-era-of-emerging-therapies\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?<\/span> &rarr;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/153"}],"collection":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/comments?post=153"}],"version-history":[{"count":1,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/153\/revisions"}],"predecessor-version":[{"id":154,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/posts\/153\/revisions\/154"}],"wp:attachment":[{"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/media?parent=153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/categories?post=153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hepbunited.org\/blog\/wp-json\/wp\/v2\/tags?post=153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}